Techniques for detection of minimal residual disease

Carmelo Carlo-Stella, Lina Mangoni, Gian Pietro Dotti, Vittorio Rizzoli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations, mainly related to its sensitivity and specificity. The general limitations of such tests originates from the size of the sample which can be analysed and the heterogeneous distribution of leukemia after treatment. Clinically useful methods for detecting residual leukemia require not only sensitivity but also speed and reproducibility. The rate of false negative tests is low with polymerase chain reaction as well as flow cytomeitric analysis. Usually, patients without persistent cells carrying leukemia-associated markers have a lower risk of relapse. However, the detection of a persistent marker at one time point in complete remission cannot be considered a reliable indicator of MRD, whereas increase of positive signals or reappearance of leukemic markers usually precedes relapse. It is likely that one single approach will not allow the monitoring of the majority of patients and that a combination of techniques will be needed. Definitive results will be obtained only through prospective studies in patients receiving standardised therapy. Studies in which therapeutic strategies are designed according to the results provided by techniques for detecting MRD will be necessary to assess the relevance of their contribution to the treatment of leukemia.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalLeukemia and Lymphoma
Volume18
Issue numberS1
DOIs
Publication statusPublished - 1995

Fingerprint

Residual Neoplasm
Leukemia
Therapeutics
Recurrence
Physiologic Monitoring
Sample Size
Prospective Studies
Sensitivity and Specificity
Polymerase Chain Reaction

Keywords

  • Acute leukemia
  • Marrow purging
  • Minimal residual disease
  • Stem cell
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Techniques for detection of minimal residual disease. / Carlo-Stella, Carmelo; Mangoni, Lina; Dotti, Gian Pietro; Rizzoli, Vittorio.

In: Leukemia and Lymphoma, Vol. 18, No. S1, 1995, p. 75-80.

Research output: Contribution to journalArticle

Carlo-Stella, Carmelo ; Mangoni, Lina ; Dotti, Gian Pietro ; Rizzoli, Vittorio. / Techniques for detection of minimal residual disease. In: Leukemia and Lymphoma. 1995 ; Vol. 18, No. S1. pp. 75-80.
@article{75e4171da8114402b563f2af80c4084c,
title = "Techniques for detection of minimal residual disease",
abstract = "Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations, mainly related to its sensitivity and specificity. The general limitations of such tests originates from the size of the sample which can be analysed and the heterogeneous distribution of leukemia after treatment. Clinically useful methods for detecting residual leukemia require not only sensitivity but also speed and reproducibility. The rate of false negative tests is low with polymerase chain reaction as well as flow cytomeitric analysis. Usually, patients without persistent cells carrying leukemia-associated markers have a lower risk of relapse. However, the detection of a persistent marker at one time point in complete remission cannot be considered a reliable indicator of MRD, whereas increase of positive signals or reappearance of leukemic markers usually precedes relapse. It is likely that one single approach will not allow the monitoring of the majority of patients and that a combination of techniques will be needed. Definitive results will be obtained only through prospective studies in patients receiving standardised therapy. Studies in which therapeutic strategies are designed according to the results provided by techniques for detecting MRD will be necessary to assess the relevance of their contribution to the treatment of leukemia.",
keywords = "Acute leukemia, Marrow purging, Minimal residual disease, Stem cell, Transplantation",
author = "Carmelo Carlo-Stella and Lina Mangoni and Dotti, {Gian Pietro} and Vittorio Rizzoli",
year = "1995",
doi = "10.3109/10428199509075308",
language = "English",
volume = "18",
pages = "75--80",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "S1",

}

TY - JOUR

T1 - Techniques for detection of minimal residual disease

AU - Carlo-Stella, Carmelo

AU - Mangoni, Lina

AU - Dotti, Gian Pietro

AU - Rizzoli, Vittorio

PY - 1995

Y1 - 1995

N2 - Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations, mainly related to its sensitivity and specificity. The general limitations of such tests originates from the size of the sample which can be analysed and the heterogeneous distribution of leukemia after treatment. Clinically useful methods for detecting residual leukemia require not only sensitivity but also speed and reproducibility. The rate of false negative tests is low with polymerase chain reaction as well as flow cytomeitric analysis. Usually, patients without persistent cells carrying leukemia-associated markers have a lower risk of relapse. However, the detection of a persistent marker at one time point in complete remission cannot be considered a reliable indicator of MRD, whereas increase of positive signals or reappearance of leukemic markers usually precedes relapse. It is likely that one single approach will not allow the monitoring of the majority of patients and that a combination of techniques will be needed. Definitive results will be obtained only through prospective studies in patients receiving standardised therapy. Studies in which therapeutic strategies are designed according to the results provided by techniques for detecting MRD will be necessary to assess the relevance of their contribution to the treatment of leukemia.

AB - Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations, mainly related to its sensitivity and specificity. The general limitations of such tests originates from the size of the sample which can be analysed and the heterogeneous distribution of leukemia after treatment. Clinically useful methods for detecting residual leukemia require not only sensitivity but also speed and reproducibility. The rate of false negative tests is low with polymerase chain reaction as well as flow cytomeitric analysis. Usually, patients without persistent cells carrying leukemia-associated markers have a lower risk of relapse. However, the detection of a persistent marker at one time point in complete remission cannot be considered a reliable indicator of MRD, whereas increase of positive signals or reappearance of leukemic markers usually precedes relapse. It is likely that one single approach will not allow the monitoring of the majority of patients and that a combination of techniques will be needed. Definitive results will be obtained only through prospective studies in patients receiving standardised therapy. Studies in which therapeutic strategies are designed according to the results provided by techniques for detecting MRD will be necessary to assess the relevance of their contribution to the treatment of leukemia.

KW - Acute leukemia

KW - Marrow purging

KW - Minimal residual disease

KW - Stem cell

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0029095748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029095748&partnerID=8YFLogxK

U2 - 10.3109/10428199509075308

DO - 10.3109/10428199509075308

M3 - Article

VL - 18

SP - 75

EP - 80

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - S1

ER -